Skip to main content

Research Repository

Advanced Search

Linking in vitro lipolysis and microsomal metabolism for the quantitative prediction of oral bioavailability of BCS II drugs administered in lipidic formulations

Benito-Gallo, Paloma; Marlow, Maria; Zann, Vanessa; Scholes, Peter; Gershkovich, Pavel

Authors

Paloma Benito-Gallo

Vanessa Zann

Peter Scholes



Abstract

Lipidic formulations (LFs) are increasingly utilized for the delivery of drugs that belong to class II of the Biopharmaceutics Classification System (BCS). The current work proposes, for the first time, the combination of in vitro lipolysis and microsomal metabolism studies for the quantitative prediction of human oral bioavailability of BCS II drugs administered in LFs. Marinol® and Neoral® were selected as model LFs and their observed oral bioavailabilities (Fobserved) obtained from published clinical studies in humans. Two separate lipolysis buffers, differing in the level of surfactant concentrations, were used for digestion of the LFs. The predicted fraction absorbed (Fabs) was calculated by measuring the drug concentration in the micellar phase after completion of the lipolysis process. To determine first-pass metabolism (Fg∙Fh), drug depletion studies with human microsomes were performed. Clearance values were determined by applying the “in vitro half-life approach”. The estimated Fabs and Fg∙Fh values were combined for the calculation of the predicted oral bioavailability (Fpredicted). Results showed that there was a strong correlation between Fobserved and Fpredicted values only when Fabs was calculated using a buffer with surfactant concentrations closer to physiological conditions. The general accuracy of the predicted values suggests that the novel in vitro lipolysis/metabolism approach could quantitatively predict the oral bioavailability of lipophilic drugs administered in LFs.

Citation

Benito-Gallo, P., Marlow, M., Zann, V., Scholes, P., & Gershkovich, P. (in press). Linking in vitro lipolysis and microsomal metabolism for the quantitative prediction of oral bioavailability of BCS II drugs administered in lipidic formulations. Molecular Pharmaceutics, 13(10), https://doi.org/10.1021/acs.molpharmaceut.6b00597

Journal Article Type Article
Acceptance Date Aug 24, 2016
Online Publication Date Aug 24, 2016
Deposit Date Sep 20, 2016
Publicly Available Date Sep 20, 2016
Journal Molecular Pharmaceutics
Print ISSN 1543-8384
Electronic ISSN 1543-8392
Publisher American Chemical Society
Peer Reviewed Peer Reviewed
Volume 13
Issue 10
DOI https://doi.org/10.1021/acs.molpharmaceut.6b00597
Keywords In vitro lipolysis; microsomal metabolism; IVIVC; oral bioavailability; ?9-Tetrahydrocannabinol; Cyclosporine A
Public URL https://nottingham-repository.worktribe.com/output/804728
Publisher URL http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00597
Related Public URLs http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.6b00597

Files

acs%2Emolpharmaceut%2E6b00597.pdf (1.2 Mb)
PDF

Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0





You might also like



Downloadable Citations